Rosiglitazone does not raise heart risk in diabetes

07/23/2013 | MedPage Today (free registration)

Rosiglitazone did not appear to increase the risk of major cardiac events and death in diabetes patients with coronary artery disease compared with patients not taking a thiazolidinedione-based drug, according to an analysis in the journal Circulation. Researchers also found a lower incidence of the composite of death, myocardial infarction and stroke in patients taking rosiglitazone.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC